Cargando…

Frequency of Potential Drug–Drug Interactions in the Changing Field of HCV Therapy

BACKGROUND: With the introduction of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection, drug–drug interactions (DDIs) emerged as significant challenge. Since then, HCV therapy and the infected population have rapidly changed. So far, very limited data are available regarding the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schulte, Benjamin, Wübbolding, Maximilian, Marra, Fiona, Port, Kerstin, Manns, Michael P, Back, David, Cornberg, Markus, Stichtenoth, Dirk O, Höner zu Siederdissen, Christoph, Maasoumy, Benjamin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033915/ https://www.ncbi.nlm.nih.gov/pubmed/32104719 http://dx.doi.org/10.1093/ofid/ofaa040

Ejemplares similares

Frequency, characteristics and impact of multiple consecutive nosocomial infections in patients with decompensated liver cirrhosis and ascites
por: Schultalbers, Marie, et al.
Publicado: (2020)

Duplicate prescriptions—proposal of a clinically oriented categorisation
por: Heck, Johannes, et al.
Publicado: (2021)

Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications
por: Marra, Fiona, et al.
Publicado: (2018)

The role of HBsAg levels in the current management of chronic HBV infection
por: Höner zu Siederdissen, Christoph, et al.
Publicado: (2014)

Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg‐Negative CHB
por: Wübbolding, Maximilian, et al.
Publicado: (2020)

Antimicrobial resistance in patients with decompensated liver cirrhosis and bacterial infections in a tertiary center in Northern Germany
por: Hillert, Annika, et al.
Publicado: (2021)

Interdependent Impact of Lipoprotein Receptors and Lipid-Lowering Drugs on HCV Infectivity
por: Zapatero-Belinchón, Francisco J., et al.
Publicado: (2021)

Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction—A Real-world Experience
por: Sandmann, Lisa, et al.
Publicado: (2021)

Long-Lasting Imprint in the Soluble Inflammatory Milieu Despite Early Treatment of Acute Symptomatic Hepatitis C
por: Khera, Tanvi, et al.
Publicado: (2021)

Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy
por: Mücke, Marcus M., et al.
Publicado: (2019)

Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting
por: Maasoumy, Benjamin, et al.
Publicado: (2013)

Duplicate prescriptions in the emergency department: a retrospective cohort study
por: Heck, Johannes, et al.
Publicado: (2022)

Impact of HCV Testing and Treatment on HCV Transmission Among Men Who Have Sex With Men and Who Inject Drugs in San Francisco: A Modelling Analysis
por: Artenie, Adelina, et al.
Publicado: (2023)

Association Between Type 2 Diabetes Mellitus, HbA1c and the Risk for Spontaneous Bacterial Peritonitis in Patients with Decompensated Liver Cirrhosis and Ascites
por: Tergast, Tammo L., et al.
Publicado: (2018)

Hepatitis C Virus Treatment Access Among Human Immunodeficiency Virus and Hepatitis C Virus (HCV)-Coinfected People Who Inject Drugs in Guangzhou, China: Implications for HCV Treatment Expansion
por: Chu, Carissa E., et al.
Publicado: (2016)

Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study
por: Maasoumy, Benjamin, et al.
Publicado: (2022)

New drug interactions in HIV and HCV
por: Back, David
Publicado: (2012)

Daily Low-Volume Paracentesis and Clinical Complications in Patients With Refractory Ascites
por: Tergast, Tammo L., et al.
Publicado: (2023)

Discriminatory power of RNA family models
por: zu Siederdissen, Christian Höner, et al.
Publicado: (2010)

Real-world Efficacy of Direct-Acting Antiviral Therapy for HCV Infection Affecting People Who Inject Drugs Delivered in a Multidisciplinary Setting
por: Alimohammadi, Arshia, et al.
Publicado: (2018)

A Randomized Controlled Trial of Cash Incentives or Peer Support to Increase HCV Treatment for Persons With HIV Who Use Drugs: The CHAMPS Study
por: Ward, Kathleen M, et al.
Publicado: (2019)

Breakthroughs in hepatitis C research: from discovery to cure
por: Manns, Michael P., et al.
Publicado: (2022)

Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic
por: Sansom, Sarah E, et al.
Publicado: (2019)

Automatic, fast, hierarchical, and non-overlapping gating of flow cytometric data with flowEMMi v2
por: Bruckmann, Carmen, et al.
Publicado: (2022)

Decoding cell-type contributions to the cfRNA transcriptomic landscape of liver cancer
por: Safrastyan, Aram, et al.
Publicado: (2023)

Sustained impact of nosocomial-acquired spontaneous bacterial peritonitis in different stages of decompensated liver cirrhosis
por: Kimmann, Markus, et al.
Publicado: (2019)

Role of HCV Viremia in Corroborated HCV Transmission Events Within Young Adult Injecting Partnerships
por: Hahn, Judith A, et al.
Publicado: (2019)

Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response
por: Meyer, Manuela F, et al.
Publicado: (2007)

Nosocomial infections in female compared with male patients with decompensated liver cirrhosis
por: Griemsmann, Marie, et al.
Publicado: (2022)

CMCompare webserver: comparing RNA families via covariance models
por: Eggenhofer, Florian, et al.
Publicado: (2013)

Predicting RNA 3D structure using a coarse-grain helix-centered model
por: Kerpedjiev, Peter, et al.
Publicado: (2015)

RNAlien – Unsupervised RNA family model construction
por: Eggenhofer, Florian, et al.
Publicado: (2016)

Intervention Packages to Reduce the Impact of HIV and HCV Infections Among People Who Inject Drugs in Eastern Europe and Central Asia: A Modeling and Cost-effectiveness Study
por: Mabileau, Guillaume, et al.
Publicado: (2018)

Optimizing Hepatitis C Virus (HCV) Treatment in a US Colocated HCV/Opioid Agonist Therapy Program
por: Habchi, Jackie, et al.
Publicado: (2020)

Remdesivir-induced symmetrical drug–related intertriginous and flexural exanthema (SDRIFE)? A case report with review of the literature
por: Heck, Johannes, et al.
Publicado: (2020)

Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis
por: Marra, Fawziah, et al.
Publicado: (2016)

T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral Therapy
por: Auma, Ann W N, et al.
Publicado: (2021)

Algebraic Dynamic Programming over general data structures
por: zu Siederdissen, Christian Höner, et al.
Publicado: (2015)

HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta
por: Sandmann, Lisa, et al.
Publicado: (2021)

Performance of Two HCV RNA Assays during Protease Inhibitor-Based Triple Therapy in Patients with Advanced Liver Fibrosis and Cirrhosis
por: Maasoumy, Benjamin, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_nle0psldtqjtfhj2hao7q12bj6